Last reviewed · How we verify
Standard of care therapy — Competitive Intelligence Brief
phase 3
Oncology
Biologic
Live · refreshed every 30 min
Target snapshot
Standard of care therapy (Standard of care therapy) — Oxford BioMedica. This drug is a standard of care therapy.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Standard of care therapy TARGET | Standard of care therapy | Oxford BioMedica | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Standard of care therapy CI watch — RSS
- Standard of care therapy CI watch — Atom
- Standard of care therapy CI watch — JSON
- Standard of care therapy alone — RSS
Cite this brief
Drug Landscape (2026). Standard of care therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/standard-of-care-therapy. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab